according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 04/14/2025 402657-00021 Date of first issue: 12/11/2015 7.0

SECTION 1. IDENTIFICATION

Product name Ribavirin Solid Formulation

Manufacturer or supplier's details

Company name of supplier Merck & Co., Inc Address 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone 908-740-4000 Emergency telephone 1-908-423-6000

E-mail address EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Not applicable Restrictions on use

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Germ cell mutagenicity Category 2

Reproductive toxicity Category 1B

Specific target organ toxicity

single exposure

Category 3

Specific target organ toxicity : Category 1 (Blood)

repeated exposure (Oral)

Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

GHS label elements

Hazard pictograms





Signal Word Danger

Hazard Statements If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H335 May cause respiratory irritation.

H341 Suspected of causing genetic defects.

H360Df May damage the unborn child. Suspected of damaging

fertility.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

H372 Causes damage to organs (Blood) through prolonged or

repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel

unwell.

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Ribavirin	36791-04-5*	>= 60 - <= 80	TSC
Cellulose	9004-34-6*	>= 10 - <= 30	TSC
Magnesium stearate	557-04-0*	>= 0.5 - <= 1.5	TSC

^{*} Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention.
Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

May cause respiratory irritation. Suspected of causing genetic defects.

May damage the unborn child. Suspected of damaging

fertility.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 04/14/2025 402657-00021 Date of first issue: 12/11/2015 7.0

SECTION 6. ACCIDENTAL RELEASE MEASURES

tive equipment and emer-

gency procedures

Personal precautions, protec- : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

If sufficient ventilation is unavailable, use with local exhaust Local/Total ventilation

ventilation.

Do not get on skin or clothing. Advice on safe handling

> Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Minimize dust generation and accumulation.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

> Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 mg/m³

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m³

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

10 ma/m³

ticulates

Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

5 mg/m³

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Ribavirin	36791-04-5	Wipe limit	400 μg/100 cm ²	Internal
		TWA	40 μg/m3 (OEB 3)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Res-	5 mg/m³	NIOSH REL

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/30/2023

 7.0
 04/14/2025
 402657-00021
 Date of first issue: 12/11/2015

II		pirable)		
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

Engineering measures :

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where

concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature No data available

Decomposition temperature No data available

Viscosity

Viscosity, kinematic Not applicable

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

> Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute toxicity estimate: 2,249 mg/kg Acute oral toxicity

Method: Calculation method

Components:

Ribavirin:

Acute oral toxicity LD50 (Rat): 4,116 - 5,584 mg/kg

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

LD50 (Mouse): > 10,000 mg/kg

LD50 (Dog): >= 1,500 mg/kg

Acute inhalation toxicity Remarks: No data available

Acute dermal toxicity Remarks: No data available

administration)

Acute toxicity (other routes of : LD50 (Rat): 1,554 - 1,758 mg/kg

Application Route: Intraperitoneal

LD50 (Mouse): 1,268 mg/kg Application Route: Intraperitoneal

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks No data available May irritate skin.

Magnesium stearate:

Species Rabbit

Result No skin irritation

Remarks Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Components:

Ribavirin:

Remarks : No data available

May irritate eyes.

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Ribavirin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Rodent cell line

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test

Species: Rat Result: negative

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Test Type: Mouse Lymphoma

Species: Mouse Result: positive

Test Type: Micronucleus test

Species: Mouse Result: positive

Germ cell mutagenicity -

Assessment

Positive result(s) from in vivo mammalian somatic cell muta-

genicity tests.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Ribavirin:

Species : Mouse
Application Route : Oral
Exposure time : 6 Months

LOAEL : 75 mg/kg body weight

Result : negative Target Organs : Blood, Testes

Remarks : The mechanism or mode of action may not be relevant in hu-

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

mans.

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 10 mg/kg body weight

Result : negative

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Species : Mouse
Application Route : Oral
Exposure time : 18 Months
Result : negative

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

Ribavirin:

Effects on fertility : Test Type: Fertility

Species: Rat, male

Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight

Symptoms: Reduced fertility

Result: positive

Test Type: Fertility Species: Mouse, male Application Route: Oral

Fertility: LOAEL: 35 mg/kg body weight

Symptoms: Reduced fertility

Result: positive

Test Type: Fertility

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Species: Rat, females Application Route: Oral

Fertility: NOAEL: 10 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, male Application Route: Oral

Fertility: NOAEL: 160 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat, female Application Route: Oral

Developmental Toxicity: LOAEL: <= 1 mg/kg body weight Symptoms: Reduced body weight, Reduced number of viable

fetuses., Skeletal malformations.

Result: Embryotoxic effects and adverse effects on the

offspring were detected.

Test Type: Development Species: Rabbit, female Application Route: Oral

General Toxicity Maternal: LOAEL: 1 mg/kg body weight Developmental Toxicity: LOAEL: 1 mg/kg body weight Symptoms: Reduced body weight, Skeletal malformations. Result: Embryotoxic effects and adverse effects on the

offspring were detected.

Test Type: Development Species: Hamster Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Symptoms: Skeletal and visceral variations ., Total Resorp-

tions / resorption rate.

Result: Embryotoxic effects and adverse effects on the

offspring were detected.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.3 mg/kg body weight Embryo-fetal toxicity.: LOAEL: 1 mg/kg body weight

Symptoms: Skeletal malformations.

Result: positive

Reproductive toxicity - As-

sessment

 Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of

adverse effects on development, based on animal

experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT-single exposure

May cause respiratory irritation.

Components:

Ribavirin:

Assessment : May cause respiratory irritation.

STOT-repeated exposure

Causes damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Components:

Ribavirin:

Routes of exposure : Ingestion Target Organs : Blood

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Ribavirin:

Species : Monkey LOAEL : 30 mg/kg Exposure time : 10 d

Target Organs : Blood, Gastrointestinal tract

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Species Rat NOAEL 7.6 mg/kg Application Route Inhalation : Exposure time 90 d

Target Organs Blood, Lungs

Species Dog NOAEL 5 mg/kg Application Route : Oral Exposure time 1 y

Target Organs Blood, Gastrointestinal tract

Species Mouse NOAEL 20 mg/kg Application Route : Oral Exposure time : 18 Months

Target Organs : Blood, Cardio-vascular system

Cellulose:

Species Rat

NOAEL >= 9,000 mg/kgApplication Route Ingestion Exposure time : 90 Days

Magnesium stearate:

Species : Rat

: > 100 mg/kgNOAEL Application Route : Ingestion Exposure time 90 Days

Remarks Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ribavirin:

Inhalation Symptoms: Headache, Dizziness Remarks: Based on Human Evidence Skin contact

Remarks: May cause eye irritation.

Based on Human Evidence

Eye contact : Remarks: May cause eye irritation.

Based on Human Evidence

Symptoms: blood effects, immune system effects, anorexia, Ingestion

Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver

function change, Gastrointestinal disturbance

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 04/14/2025 402657-00021 Date of first issue: 12/11/2015 7.0

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ribavirin:

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 117 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: EC50 (Pseudokirchneriella subcapitata (green algae)): > 119

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 6.9

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to microorganisms EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Toxicity to fish

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other:

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Ribavirin:

Partition coefficient: n-

octanol/water

log Pow: 0.971

Magnesium stearate:

Partition coefficient: n-

octanol/water

: $\log Pow: > 4$

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Germ cell mutagenicity Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Ribavirin 36791-04-5 Cellulose 9004-34-6 D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate 64044-51-5

California Prop. 65

WARNING: This product can expose you to chemicals including Ribavirin, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

California List of Hazardous Substances

Ribavirin 36791-04-5

California Permissible Exposure Limits for Chemical Contaminants

Cellulose 9004-34-6 Magnesium stearate 557-04-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

Health 0 Instability

Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8. Article 107)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average CAL PEL / PEL : Permissible exposure limit

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

OSHA Z-1 / TWA : 8-hour time weighted average OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory: TECI - Thailand Existing Chemicals Inventory: TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 04/14/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

according to the OSHA Hazard Communication Standard



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 7.0 04/14/2025 402657-00021 Date of first issue: 12/11/2015

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8